Market closedNon-fractionalADR
Bicycle Therapeutics/BCYC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Bicycle Therapeutics
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology. Its product candidates also include BT1718 and BT7455.
Ticker
BCYC
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Cambridge, United Kingdom
Employees
284
Website
www.bicycletherapeutics.com
BCYC Metrics
BasicAdvanced
$1.5B
Market cap
-
P/E ratio
-$4.45
EPS
0.87
Beta
-
Dividend rate
Price and volume
Market cap
$1.5B
Beta
0.87
52-week high
$28.91
52-week low
$12.54
Average daily volume
8.1
Financial strength
Current ratio
10.421
Long term debt to equity
8.651
Total debt to equity
8.651
Management effectiveness
Return on assets (TTM)
-34.46%
Return on equity (TTM)
-56.13%
Return on investment (TTM)
-38.51%
Valuation
Price to revenue (TTM)
36.643
Price to tangible book (TTM)
4.282
Growth
Revenue change (TTM)
168.47%
Earnings per share change (TTM)
-6.72%
3-year revenue growth (CAGR)
37.44%
What the Analysts think about BCYC
Analyst Ratings
Majority rating from 11 analysts.
BCYC Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$20M
267.92%
Net income
-$27M
-45.92%
Profit margin
-135.89%
-85.30%
BCYC Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.41
-$1.26
-$1.16
-$0.62
-
Expected
-$1.29
-$1.17
-$1.23
-$1.24
-$1.14
Surprise
9.02%
7.56%
-5.95%
-50.15%
-
BCYC News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bicycle Therapeutics stock?
Bicycle Therapeutics (BCYC) has a market cap of $1.5B as of July 27, 2024.
What is the P/E ratio for Bicycle Therapeutics stock?
The price to earnings (P/E) ratio for Bicycle Therapeutics (BCYC) stock is 0 as of July 27, 2024.
Does Bicycle Therapeutics stock pay dividends?
No, Bicycle Therapeutics (BCYC) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Bicycle Therapeutics dividend payment date?
Bicycle Therapeutics (BCYC) stock does not pay dividends to its shareholders.
What is the beta indicator for Bicycle Therapeutics?
Bicycle Therapeutics (BCYC) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Bicycle Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.